Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ESR1 | P03372 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14956919 | 0.94 | ALDH1A1 (0.55) | SMN1; SMN2ESR1L3MBTL1RAB9ANPC1 | |
| SCHEMBL17484853 | 0.92 | ESR1 (0.56) | SMN1; SMN2ESR1L3MBTL1RAB9ANPC1 | |
| SCHEMBL13308494 | 0.92 | ESR1 (0.56) | SMN1; SMN2ESR1L3MBTL1RAB9ANPC1 | |
| SCHEMBL14015788 | 0.92 | ESR1 (0.56) | SMN1; SMN2ESR1L3MBTL1RAB9ANPC1 | |
| SCHEMBL11956138 | 0.92 | ESR1 (0.56) | SMN1; SMN2ESR1L3MBTL1RAB9ANPC1 | |
| SCHEMBL2713160 | 0.92 | ESR1 (0.56) | SMN1; SMN2ESR1L3MBTL1RAB9ANPC1 | |
| SCHEMBL14382370 | 0.92 | ESR1 (0.56) | SMN1; SMN2ESR1L3MBTL1RAB9ANPC1 | |
| SCHEMBL11790 | 0.90 | SMN1; SMN2 (0.56) | SMN1; SMN2ESR1L3MBTL1RAB9ANPC1 | |
| SCHEMBL9011867 | 0.90 | SMN1; SMN2 (0.59) | SMN1; SMN2L3MBTL1RAB9ANPC1NFKB1 | |
| SCHEMBL9011602 | 0.88 | SMN1; SMN2 (0.57) | SMN1; SMN2L3MBTL1RAB9ANPC1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151159-A1 | COMPOUND FOR FORMING HARDMASK, HARDMASK COMPOSITION INCLUDING THE COMPOUND, AND METHOD OF MANUFACTURING INTEGRATED CIRCUIT DEVICE USING THE HARDMASK COMPOSITION | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| US-20200223871-A1 | Arginase Inhibitors and Methods of Use | ASTRAZENECA AB (SE) | 2020-07-16 | — | — | US | disclosed |
| EP-2389352-B1 | ARGINASE INHIBITORS AND METHODS OF USE | UNIV PENNSYLVANIA (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20190127395-A1 | Arginase Inhibitors and Methods of Use | ASTRAZENECA AB (SE) | 2019-05-02 | — | — | US | disclosed |
| EP-2602254-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-20160194340-A1 | ARGINASE INHIBITORS AND METHODS OF USE | UNIV PENNSYLVANIA (US) | 2016-07-07 | — | — | US | disclosed |
| US-20160031854-A1 | ACTIVATION OR REACTIVATION OF ACHE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-02-04 | — | — | US | disclosed |
| US-8895583-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20130210798-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| US-8367282-B2 | Compound or its tautomer, metal complex compound, colored photosensitive curing composition, color filter, and production | FUJIFILM CORPORATION (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20080249175-A1 | N-Phenyloxamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| US-7425408-B2 | Silver halide color photographic light-sensitive material | FUJIFILM CORPORATION (JP) | 2008-09-16 | — | — | US | disclosed |
| US-7404632-B2 | Ink-jet recording ink and image forming method | FUJIFILM CORPORATION (JP) | 2008-07-29 | — | — | US | disclosed |
| US-20080113305-A1 | SILVER HALIDE COLOR PHOTOGRAPHIC LIGHT-SENSITIVE MATERIAL | FUJIFILM CORPORATION | 2008-05-15 | — | — | US | disclosed |
| US-20080076044-A1 | Compound or its tautomer, metal complex compound, colored photosensitive curing composition, color filter, and production | FUJIFILM CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080043078-A1 | Ink Set and Ink Jet Recording Method | FUJIFILM CORPORATION (JP) | 2008-02-21 | — | — | US | disclosed |
| EP-1636215-B1 | FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7223453-B2 | Ink jet recording medium and ink jet recording method | FUJIFILM CORPORATION (JP) | 2007-05-29 | — | — | US | disclosed |
| US-20070054224-A1 | Silver halide color photographic light-sensitive material | FUJI PHOTO FILM CO., LTD. | 2007-03-08 | — | — | US | disclosed |
| US-7183044-B2 | Silver halide color photographic light-sensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 2007-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249175-A1 | N-Phenyloxamide derivatives | SERPINE1, SERPINH1, F12 | SMN1; SMN2 3040/4885ESR1 2818/4885L3MBTL1 1734/4885 |
| US-20200223871-A1 | Arginase Inhibitors and Methods of Use | ARG1, ARG2, NOS2 | SMN1; SMN2 3214/4885ESR1 4830/4885L3MBTL1 4838/4885 |
| US-20130210798-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1B1, GUCY1A1, GUCY1A2 | SMN1; SMN2 1437/4885ESR1 952/4885L3MBTL1 3366/4885 |
| US-20160194340-A1 | ARGINASE INHIBITORS AND METHODS OF USE | ARG1, ARG2, NOS2 | SMN1; SMN2 3214/4885ESR1 4830/4885L3MBTL1 4838/4885 |
| US-20190127395-A1 | Arginase Inhibitors and Methods of Use | ARG1, ARG2, NOS2 | SMN1; SMN2 3214/4885ESR1 4830/4885L3MBTL1 4838/4885 |
| US-20080076044-A1 | Compound or its tautomer, metal complex compound, colored photosensitive curing composition, color filter, and production | PBRM1, CRY1, MAPT | SMN1; SMN2 3115/4885ESR1 1877/4885L3MBTL1 3869/4885 |
| US-20160031854-A1 | ACTIVATION OR REACTIVATION OF ACHE | ACHE, BCHE, CHAT | SMN1; SMN2 470/4885ESR1 3961/4885L3MBTL1 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.